These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 16258518

  • 1. Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas.
    Korja M, Finne J, Salmi TT, Kalimo H, Karikoski R, Tanner M, Isola J, Haapasalo H.
    Mod Pathol; 2005 Dec; 18(12):1599-605. PubMed ID: 16258518
    [Abstract] [Full Text] [Related]

  • 2. Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH): an alternative and practical method.
    Bhargava R, Oppenheimer O, Gerald W, Jhanwar SC, Chen B.
    Diagn Mol Pathol; 2005 Jun; 14(2):72-6. PubMed ID: 15905689
    [Abstract] [Full Text] [Related]

  • 3. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
    Tsai HY, Hsi BL, Hung IJ, Yang CP, Lin JN, Chen JC, Tsai SF, Huang SF.
    Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J, Edsjö A, De Preter K, Axelson H, Speleman F, Påhlman S.
    Oncogene; 2003 Jan 23; 22(3):456-60. PubMed ID: 12545167
    [Abstract] [Full Text] [Related]

  • 6. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q, Hii G, Shusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM.
    Cancer Res; 2003 Apr 01; 63(7):1631-5. PubMed ID: 12670915
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Assessment of MYCN amplification status in Tunisian neuroblastoma: CISH and MLPA combining approach.
    H'Mida Ben Brahim D, Trabelsi S, Chabchoub I, Gargouri I, Harrabi I, Moussa A, Chourabi M, Haddaji M, Sassi S, Mougou S, Gribaa M, Ben Ahmed S, Zakhama A, Nouri A, Saad A.
    Tunis Med; 2015 Apr 01; 93(8-9):527-31. PubMed ID: 26815518
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, König R, Fischer M, Schwab M.
    Genome Biol; 2008 Oct 13; 9(10):R150. PubMed ID: 18851746
    [Abstract] [Full Text] [Related]

  • 11. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG.
    FASEB J; 2011 Dec 13; 25(12):4138-49. PubMed ID: 21856782
    [Abstract] [Full Text] [Related]

  • 12. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M, Zhou C, Cai R, Li Y, Gong L.
    Diagn Pathol; 2013 Jan 15; 8():5. PubMed ID: 23320395
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Concomitant DDX1 and MYCN gain in neuroblastoma.
    Defferrari R, Tonini GP, Conte M, Papio F, Sementa AR, Valent A, Schena F, Perri P, Mazzocco K.
    Cancer Lett; 2007 Oct 18; 256(1):56-63. PubMed ID: 17611020
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H.
    Cancer; 2013 Oct 15; 119(20):3718-26. PubMed ID: 23901000
    [Abstract] [Full Text] [Related]

  • 20. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J, Regan PL, Edo R, Leonhardt P, Jeng EI, Rappaport EF, Ikegaki N, Tang XX.
    Int J Oncol; 2010 Oct 15; 37(4):983-91. PubMed ID: 20811720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.